GILD · News · 20260806N

Acquisition-Related R&D Charges

GILEAD SCIENCES, INC. · 2026-08-06 · Importance 96 · Surprise 100

Gilead swung to a second-quarter net loss of approximately $10.5 billion, compared with net income of $2.01 per diluted share in the year-ago quarter. The loss was primarily driven by acquired in-process research and development expenses associated with recent acquisitions, including a substantial impairment related to a discontinued non-small-cell lung cancer program. Adjusted diluted loss was reported at $6.75 per share, and the company forecast a full-year 2026 adjusted loss of $0.30 to $0.65 per share.

Key facts

• The Q2 2026 loss included significant acquired IPR&D expenses and an impairment related to a discontinued NSCLC program. source